Entry - #613558 - DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51 - OMIM
# 613558

DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51


Alternative titles; symbols

CHROMOSOME 9q21.11 DUPLICATION SYNDROME


Cytogenetic location: 9q21.11     Genomic coordinates (GRCh38): 9:65,000,001-69,300,000


Gene-Phenotype Relationships
Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
9q21.11 Deafness, autosomal dominant 51 613558 AD 4
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
HEAD & NECK
Ears
- Hearing loss, age-related
MISCELLANEOUS
- Onset in the fourth decade
- Progressive disorder
MOLECULAR BASIS
- Contiguous gene syndrome caused by duplication (269kb) on 9q21.11 including the tight junction protein 2 (TJP2, 607709) gene and the family with sequence similarity 189, member A2 (FAM189A2, 607710) gene
Deafness, autosomal dominant - PS124900 - 76 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.12 Deafness, autosomal dominant 85 AD 3 620227 USP48 617445
1p34.3 Deafness, autosomal dominant 2B AD 3 612644 GJB3 603324
1p34.3 ?Deafness, autosomal dominant 88 AD 3 620283 EPHA10 611123
1p34.2 Deafness, autosomal dominant 2A AD 3 600101 KCNQ4 603537
1p21.1 Deafness, autosomal dominant 37 AD 3 618533 COL11A1 120280
1q21-q23 Deafness, autosomal dominant 49 AD 2 608372 DFNA49 608372
1q21.3 Deafness, autosomal dominant 87 AD 3 620281 PI4KB 602758
1q23.3 Deafness, autosomal dominant 7 AD 3 601412 LMX1A 600298
1q44 Deafness, autosomal dominant 34, with or without inflammation AD 3 617772 NLRP3 606416
2p21-p12 Deafness, autosomal dominant 58 AD 4 615654 DFNA58 615654
2p12 Deafness, autosomal dominant 43 AD 2 608394 DFNA43 608394
2p11.2 ?Deafness, autosomal dominant 81 AD 3 619500 ELMOD3 615427
2q23-q24.3 Deafness, autosomal dominant 16 AD 2 603964 DFNA16 603964
3p25.3 Deafness, autosomal dominant 82 AD 3 619804 ATP2B2 108733
3q21.3 ?Deafness, autosomal dominant 70 AD 3 616968 MCM2 116945
3q22 Deafness, autosomal dominant 18 AD 2 606012 DFNA18 606012
3q23 Deafness, autosomal dominant 76 AD 3 618787 PLS1 602734
3q28 ?Deafness, autosomal dominant 44 AD 3 607453 CCDC50 611051
4p16.1 Deafness, autosomal dominant 6/14/38 AD 3 600965 WFS1 606201
4q12 Deafness, autosomal dominant 27 AD 3 612431 REST 600571
4q21.22 ?Deafness, autosomal dominant 79 AD 3 619086 SCD5 608370
4q22.2 ?Deafness, autosomal dominant 89 AD 3 620284 ATOH1 601461
4q35-qter Deafness, autosomal dominant 24 AD 2 606282 DFNA24 606282
5q13.2 ?Deafness, autosomal dominant 83 AD 3 619808 MAP1B 157129
5q23.3 Deafness, autosomal dominant 78 AD 3 619081 SLC12A2 600840
5q31.1-q32 Deafness, autosomal dominant 52 AD 2 607683 DFNA52 607683
5q31 Deafness, autosomal dominant 54 AD 2 615649 DFNA54 615649
5q31.3 Deafness, autosomal dominant 1, with or without thrombocytopenia AD 3 124900 DIAPH1 602121
5q32 Deafness, autosomal dominant 15 AD 3 602459 POU4F3 602460
6p22.3 Deafness, autosomal dominant 21 AD 3 607017 RIPOR2 611410
6p21.3 Deafness, autosomal dominant 31 AD 2 608645 DFNA31 608645
6p21.33 ?Deafness, autosomal dominant 72 AD 3 617606 SLC44A4 606107
6p21.32 Deafness, autosomal dominant 13 AD 3 601868 COL11A2 120290
6q14.1 Deafness, autosomal dominant 22 AD 3 606346 MYO6 600970
6q14.1 Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy AD 3 606346 MYO6 600970
6q21 ?Deafness, autosomal dominant 66 AD 3 616969 CD164 603356
6q23.2 Deafness, autosomal dominant 10 AD 3 601316 EYA4 603550
7p15.3 Deafness, autosomal dominant 5 AD 3 600994 GSDME 608798
7p14.3 ?Deafness, autosomal dominant 74 AD 3 618140 PDE1C 602987
7q22.1 ?Deafness, autosomal dominant 75 AD 3 618778 TRRAP 603015
7q32.2 Deafness, autosomal dominant 50 AD 3 613074 MIR96 611606
8q22.3 Deafness, autosomal dominant 28 AD 3 608641 GRHL2 608576
9p22-p21 Deafness, autosomal dominant 47 AD 2 608652 DFNA47 608652
9q21.11 Deafness, autosomal dominant 51 AD 4 613558 DFNA51 613558
9q21.13 Deafness, autosomal dominant 36 AD 3 606705 TMC1 606706
9q33.1 Deafness, autosomal dominant 56 AD 3 615629 TNC 187380
10p12.1 Deafness, autosomal dominant 90 AD 3 620722 MYO3A 606808
11p14.2-q12.3 Deafness, autosomal dominant 59 AD 2 612642 DFNA59 612642
11q13.5 Deafness, autosomal dominant 11 AD 3 601317 MYO7A 276903
11q23.3 Deafness, autosomal dominant 8/12 AD 3 601543 TECTA 602574
12q13-q14 Deafness, autosomal dominant 48 AD 2 607841 DFNA48 607841
12q21.31 Deafness, autosomal dominant 73 AD 3 617663 PTPRQ 603317
12q21.32 Deafness, autosomal dominant 69, unilateral or asymmetric AD 3 616697 KITLG 184745
12q23.1 Deafness, autosomal dominant 25 AD 3 605583 SLC17A8 607557
12q24.31 Deafness, autosomal dominant 64 AD 3 614152 DIABLO 605219
12q24.33 Deafness, autosomal dominant 41 AD 3 608224 P2RX2 600844
13q12.11 Deafness, autosomal dominant 3A AD 3 601544 GJB2 121011
13q12.11 Deafness, autosomal dominant 3B AD 3 612643 GJB6 604418
13q34 Deafness, autosomal dominant 33 AD 2 614211 DFNA33 614211
13q34 Deafness, autosomal dominant 84 AD 3 619810 ATP11A 605868
14q11.2-q12 Deafness, autosomal dominant 53 AD 2 609965 DFNA53 609965
14q12 Deafness, autosomal dominant 9 AD 3 601369 COCH 603196
14q23.1 Deafness, autosomal dominant 23 AD 3 605192 SIX1 601205
15q21.2 ?Deafness, autosomal dominant 71 AD 3 617605 DMXL2 612186
15q25-q26 Deafness, autosomal dominant 30 AD 2 606451 DFNA30 606451
15q25.2 ?Deafness, autosomal dominant 68 AD 3 616707 HOMER2 604799
16p13.3 Deafness, autosomal dominant 65 AD 3 616044 TBC1D24 613577
16p13.11 ?Deafness, autosomal dominant 77 AD 3 618915 ABCC1 158343
16p12.2 Deafness, autosomal dominant 40 AD 3 616357 CRYM 123740
17q25.3 Deafness, autosomal dominant 20/26 AD 3 604717 ACTG1 102560
18p11.32 ?Deafness, autosomal dominant 86 AD 3 620280 THOC1 606930
18q11.1-q11.2 Deafness, autosomal dominant 80 AD 3 619274 GREB1L 617782
19q13.31-q13.32 Deafness, autosomal dominant 4B AD 3 614614 CEACAM16 614591
19q13.33 Deafness, autosomal dominant 4A AD 3 600652 MYH14 608568
20q13.33 Deafness, autosomal dominant 67 AD 3 616340 OSBPL2 606731
22q12.3 Deafness, autosomal dominant 17 AD 3 603622 MYH9 160775

TEXT

A number sign (#) is used with this entry because autosomal dominant deafness-51 (DFNA51) is caused by a 269-kb duplication of chromosome 9q21.11 involving the TJP2 (607709) and FAM189A2 (607710) genes.


Clinical Features

Walsh et al. (2010) reported a large 4-generation Jewish family of Tunisian descent with age-related progressive sensorineural hearing loss. Pure tone audiometry showed hearing loss with onset in the fourth decade, first affecting high frequencies and later becoming severe to profound at all frequencies. There was no evidence of vertigo, dizziness, disequilibrium, or imbalance.


Inheritance

In the family with DFNA51 reported by Walsh et al. (2010), the transmission pattern was consistent with autosomal dominant inheritance.


Mapping

By genomewide linkage analysis of a large Jewish family with age-related hearing loss, Walsh et al. (2010) identified a locus, which they designated DFNA51, on chromosome 9p13.3-q21.13 (maximum Z score of 6.56 at D9S175).


Molecular Genetics

In affected members of a large Jewish family with DFNA51, Walsh et al. (2010) identified a tandem inverted duplication of the pericentromeric region of chromosome 9 spanning positions 71,705,804 to 71,974,823 for a size of approximately 269 kb. The duplication included the entire locus for the TJP2 gene, which spans positions 71,788,971 to 71,870,124. The distal breakpoint occurred in intron 2 of the FAM189A2 gene; however, there was no evidence of a mutant FAM189A2 transcript, and no correlation of genotype with expression of full-length FAM189A2 in the family, leading the authors to focus their studies on the duplication of TJP2. No mutations in the TJP2 gene were found; the sequence of the gene in affected individuals was wildtype. Studies of mouse tissues showed that Tjp2 is developmentally regulated in the inner ear. Studies of DFNA51 patient lymphoblasts showed that endogenous levels of TJP2 were increased approximately 2-fold, consistent with overexpression of the gene resulting from the inverted duplication. This overexpression was associated with decreased amounts of phosphorylated GSK3B (605004), indicating increased GSK3B activity, which makes cells more susceptible to apoptosis. Specific analysis of apoptosis-related genes in patient lymphoblasts showed a shift in expression of BCL2 (151430) family genes, such as BID (601997), BCL2L1 (600039), and TSPO (109610), that would favor apoptosis. Walsh et al. (2010) hypothesized that TJP2 overexpression increases the susceptibility of inner ear cells to apoptosis, leading to progressive hearing loss.


REFERENCES

  1. Walsh, T., Pierce, S. B., Lenz, D. R., Brownstein, Z., Dagan-Rosenfeld, O., Shahin, H., Roeb, W., McCarthy, S., Nord, A. S., Gordon, C. R., Ben-Neriah, Z., Sebat, J., Kanaan, M., Lee, M. K., Frydman, M., King, M.-C., Avraham, K. B. Genomic duplication and overexpression of TJP2/ZO-2 leads to altered expression of apoptosis genes in progressive nonsyndromic hearing loss DFNA51. Am. J. Hum. Genet. 87: 101-109, 2010. [PubMed: 20602916, images, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 9/15/2010
carol : 01/06/2011
terry : 12/22/2010
wwang : 9/20/2010
ckniffin : 9/16/2010
ckniffin : 9/15/2010

# 613558

DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51


Alternative titles; symbols

CHROMOSOME 9q21.11 DUPLICATION SYNDROME


ORPHA: 90635;   DO: 0110577;  


Cytogenetic location: 9q21.11     Genomic coordinates (GRCh38): 9:65,000,001-69,300,000


Gene-Phenotype Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
9q21.11 Deafness, autosomal dominant 51 613558 Autosomal dominant 4

TEXT

A number sign (#) is used with this entry because autosomal dominant deafness-51 (DFNA51) is caused by a 269-kb duplication of chromosome 9q21.11 involving the TJP2 (607709) and FAM189A2 (607710) genes.


Clinical Features

Walsh et al. (2010) reported a large 4-generation Jewish family of Tunisian descent with age-related progressive sensorineural hearing loss. Pure tone audiometry showed hearing loss with onset in the fourth decade, first affecting high frequencies and later becoming severe to profound at all frequencies. There was no evidence of vertigo, dizziness, disequilibrium, or imbalance.


Inheritance

In the family with DFNA51 reported by Walsh et al. (2010), the transmission pattern was consistent with autosomal dominant inheritance.


Mapping

By genomewide linkage analysis of a large Jewish family with age-related hearing loss, Walsh et al. (2010) identified a locus, which they designated DFNA51, on chromosome 9p13.3-q21.13 (maximum Z score of 6.56 at D9S175).


Molecular Genetics

In affected members of a large Jewish family with DFNA51, Walsh et al. (2010) identified a tandem inverted duplication of the pericentromeric region of chromosome 9 spanning positions 71,705,804 to 71,974,823 for a size of approximately 269 kb. The duplication included the entire locus for the TJP2 gene, which spans positions 71,788,971 to 71,870,124. The distal breakpoint occurred in intron 2 of the FAM189A2 gene; however, there was no evidence of a mutant FAM189A2 transcript, and no correlation of genotype with expression of full-length FAM189A2 in the family, leading the authors to focus their studies on the duplication of TJP2. No mutations in the TJP2 gene were found; the sequence of the gene in affected individuals was wildtype. Studies of mouse tissues showed that Tjp2 is developmentally regulated in the inner ear. Studies of DFNA51 patient lymphoblasts showed that endogenous levels of TJP2 were increased approximately 2-fold, consistent with overexpression of the gene resulting from the inverted duplication. This overexpression was associated with decreased amounts of phosphorylated GSK3B (605004), indicating increased GSK3B activity, which makes cells more susceptible to apoptosis. Specific analysis of apoptosis-related genes in patient lymphoblasts showed a shift in expression of BCL2 (151430) family genes, such as BID (601997), BCL2L1 (600039), and TSPO (109610), that would favor apoptosis. Walsh et al. (2010) hypothesized that TJP2 overexpression increases the susceptibility of inner ear cells to apoptosis, leading to progressive hearing loss.


REFERENCES

  1. Walsh, T., Pierce, S. B., Lenz, D. R., Brownstein, Z., Dagan-Rosenfeld, O., Shahin, H., Roeb, W., McCarthy, S., Nord, A. S., Gordon, C. R., Ben-Neriah, Z., Sebat, J., Kanaan, M., Lee, M. K., Frydman, M., King, M.-C., Avraham, K. B. Genomic duplication and overexpression of TJP2/ZO-2 leads to altered expression of apoptosis genes in progressive nonsyndromic hearing loss DFNA51. Am. J. Hum. Genet. 87: 101-109, 2010. [PubMed: 20602916] [Full Text: https://doi.org/10.1016/j.ajhg.2010.05.011]


Creation Date:
Cassandra L. Kniffin : 9/15/2010

Edit History:
carol : 01/06/2011
terry : 12/22/2010
wwang : 9/20/2010
ckniffin : 9/16/2010
ckniffin : 9/15/2010